KalVista Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KALV research report →
Companywww.kalvista.com
KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
- CEO
- Benjamin L. Palleiko
- IPO
- 2015
- Employees
- 150
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $1.43B
- P/E
- -9.78
- P/S
- 12.30
- P/B
- -499.18
- EV/EBITDA
- -11.36
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.03%
- Op Margin
- -120.80%
- Net Margin
- -119.44%
- ROE
- -1057.44%
- ROIC
- -46.81%
Growth & Income
- Revenue
- $73.62M · 0.00%
- Net Income
- $-164,286,000 · 10.44%
- EPS
- $-3.23 · 12.47%
- Op Income
- $-171,838,500
- FCF YoY
- 45.66%
Performance & Tape
- 52W High
- $26.85
- 52W Low
- $9.83
- 50D MA
- $21.15
- 200D MA
- $15.79
- Beta
- -0.12
- Avg Volume
- 3.92M
Get TickerSpark's AI analysis on KALV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 17, 26 | Yea Christopher | other | 1,774 |
| May 18, 26 | Yea Christopher | sell | 1,108 |
| May 17, 26 | Yea Christopher | other | 1,774 |
| May 17, 26 | Audhya Paul K. | other | 2,419 |
| May 18, 26 | Audhya Paul K. | sell | 1,032 |
| May 17, 26 | Audhya Paul K. | other | 2,419 |
| May 17, 26 | Palleiko Benjamin L | other | 2,419 |
| May 18, 26 | Palleiko Benjamin L | sell | 1,129 |
| May 17, 26 | Palleiko Benjamin L | other | 2,419 |
| May 11, 26 | Palleiko Benjamin L | other | 7,120 |
Our KALV Coverage
We haven't published any research on KALV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KALV Report →